AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35144885
Drug: Oral trimethoprim-sulfamethoxazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim-sulfamethoxazole, twice daily for 10 days postoperatively
Trial: 35144885
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 10 days postoperatively
Trial: 35144885
Drug: Oral trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim-sulfamethoxazole
Trial: 33002436
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) plus trastuzumab emtansine (3.6 mg/kg)
Trial: 33002436
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus trastuzumab emtansine (3.6 mg/kg)
Trial: 36149321
Drug: Miconazole buccal
RxNorm normalized name: miconazole Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole buccal tablets (MBT) plus placebo
Trial: 36149321
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules plus placebo
Trial: 35840067
Drug: Amniotic suspension
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotic suspension allograft (ASA)
Trial: 35051670
Drug: Sleep study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep study screening with autoregulated positive airway therapy
Trial: 35406010
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (1200 IU/day) + DHA (500 mg)
Trial: 34620658
Drug: Bevacizumab-800CW (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-800CW (4, 5, 10 or 25 mg)
Trial: 33619202
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics alone (n=15)
Trial: 33619202
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics and immediate cranberry capsules for up to 7 days (n=15)
Trial: 33619202
Drug: Immediate cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate cranberry capsules and delayed antibiotics for self-initiation in case of non-improvement or worsening of symptoms (n=16)
Trial: 35243872
Drug: Standard-treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-treatment group
Trial: 34291590
Drug: Rivastigmine (3–6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (3–6 mg twice a day)
Trial: 35584331
Drug: 10% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% NaOCl solution (deproteinization)
Trial: 35584331
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (acid etching with 37% phosphoric acid + placebo solution + Adper Single Bond 2/3M Oral Care + Filtek Z350/3M Oral Care)
Trial: 35220503
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (FOLFOX or CAPOX)
Trial: 37028940
Drug: Pirfenidone (2403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (2403 mg/day)
Trial: 32603714
Drug: Evening long‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening long‐acting bronchodilation (aclidinium bromide/formoterol fumarate dihydrate: 400/12 μg)
Trial: 32603714
Drug: Evening long‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening long‐acting bronchodilator (aclidinium bromide/formoterol fumarate dihydrate: 400/12 μg)
Trial: 32429917
Drug: Healthy food
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy food nudges (e.g., product placement or promotion)
Trial: 34034821
Drug: Delayed Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed Intervention (DI) group - given contact information for a nearby addiction medicine clinic.
Trial: 36181412
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus FMT therapy
Trial: 36181412
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus FMT therapy with 3 administrations
Trial: 36181412
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus FMT therapy with 6 administrations
Trial: 32111579
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS over the left PFC (1.5 mA, 5-cm x 5-cm electrodes) with concurrent cathodal tDCS over the right PFC during emotion regulation task.
Trial: 34078591
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg/kg immediately after the surgical procedure, and on day 1)
Trial: 36418131
Drug: Clinically assisted
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically assisted hydration (CAH) - parenteral fluids (dextrose saline 4% dextrose, 0.18% sodium chloride)
Trial: 33822650
Drug: Intensified clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified clinical pharmacological/pharmaceutical care (medication management and structured patient counseling) over 12 weeks
Trial: 33822650
Drug: Intensified clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified clinical pharmacological/pharmaceutical care (intervention group)
Trial: 33942777
Drug: ropivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine + dexmedetomidine (1 μg/kg)
Trial: 33942777
Drug: ropivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine + fentanyl (1 μg/kg)
Trial: 33942777
Drug: ropivacaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine (40 mL/0.5%)
Trial: 33168838
Drug: Amylase quantification
RxNorm normalized name: amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylase quantification in the terminal ileum; daily analysis of ileostomy effluent for the first 5 post-operative days.
Trial: 34348529
Drug: Higher genetically
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher genetically predicted IL-1 receptor antagonist (IL-1Ra)
Trial: 34883506
Drug: Clofarabine (CLO)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine (CLO) added to induction and consolidation treatment
Trial: 35442223
Drug: Protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-based regimen
Trial: 33772746
Drug: 131I therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I therapy for low-risk DTC patients
Trial: 33772746
Drug: 131I therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I therapy for low-risk papillary thyroid microcarcinomas
Trial: 33687578
Drug: sCT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT treatment
Trial: 33615951
Drug: Daily synbiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily synbiotic supplement (5 g prebiotic fiber + 8 billion CFU probiotic B. lactis) with 140 mg ferrous sulfate (FeSO4) daily for 8 weeks
Trial: 33615951
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 140 mg ferrous sulfate (FeSO4) daily for 8 weeks
Trial: 32048788
Drug: 1 session
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 session per week of acupuncture (group L)
Trial: 34471000
Drug: curcuRougeTM (newly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: curcuRougeTM (newly developed highly bioavailable curcumin formulation) administered for 4 weeks
Trial: 33050760
Drug: Peficitinib 100
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 100 mg/day
Trial: 33050760
Drug: Peficitinib 150
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 150 mg/day
Trial: 33050760
Drug: Peficitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peficitinib (all doses)
Trial: 33434399
Drug: DAV132 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAV132 7.5 g administered concomitantly with warfarin (5 mg) and clonazepam (1 mg)
Trial: 33434399
Drug: DAV132 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAV132 7.5 g administered 1 hour before warfarin (5 mg) and clonazepam (1 mg)
Trial: 35299753
Drug: Supervised resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised resistance training for 12 weeks during adjuvant chemotherapy
Trial: 36216140
Drug: rs53576 G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs53576 G homozygotes in the neuroimaging arm
Trial: 33975171
Drug: Sertraline or
RxNorm normalized name: sertraline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline or Paroxetine
Trial: 37779358
Drug: Pioglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone plus intensive lifestyle therapy
Trial: 37779358
Drug: Conventional lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lifestyle therapy with placebo
Trial: 37779358
Drug: Intensified lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified lifestyle therapy, pioglitazone, or their combination
Trial: 33836215
Drug: Larger portion
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger portion of vegetables (120 g)
Trial: 33887408
Drug: MF-PRP HD
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-PRP HD (High Dose)
Trial: 33887408
Drug: MF-PRP LD
RxNorm normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-PRP LD (Low Dose)
Trial: 34953401
Drug: Intravenous 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% NaCl 500 ml + KCL 20 mEq over 4 h pre-cisplatin 40 mg/m2 weekly for 7-8 weeks (Control group)
Trial: 34953401
Drug: Intravenous 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% NaCl 500 ml + KCL 20 mEq + additional 16 mEq magnesium (Mg group)
Trial: 34210061
Drug: Ontario Brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontario Brain Injury Association Peer Support Program (weekly intervention)
Trial: 32531259
Drug: Sofosbuvir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (200 mg) plus ribavirin (200 mg) for 24 weeks
Trial: 32531259
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg) plus ribavirin (200 mg) for 24 weeks
Trial: 32531259
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) plus sofosbuvir (400 mg) for 12 weeks
Trial: 33781269
Drug: CAF-3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-3 (3 mg/kg/b.m.)
Trial: 33781269
Drug: CAF-6 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-6 (6 mg/kg/b.m.)
Trial: 36014925
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration for 12 weeks
Trial: 33103603
Drug: Glucagon bolus
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon bolus (50 µg/kg)
Trial: 33103603
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion (50 µg/kg)
Trial: 33103603
Drug: Esmolol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1.25 mg/kg bolus + 0.75 mg/kg/min infusion)
Trial: 32209625
Drug: G-CSF (filgrastim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (filgrastim)
Trial: 32209625
Drug: Placebo (indistinguishable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (indistinguishable glucose solution 5%)
Trial: 36375780
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of ferric carboxymaltose (FCM)
Trial: 36375780
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL of physiological serum)
Trial: 35364413
Drug: Transcutaneous vagal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous vagal nerve stimulation (tVNS) - early stimulation (4 hours daily between Day 0 and 13)
Trial: 35364413
Drug: Transcutaneous vagal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous vagal nerve stimulation (tVNS) - late stimulation (4 hours daily between Day 14 and 28)
Trial: 33249449
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and tDCS
Trial: 33249449
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and sham tDCS
Trial: 35213547
Drug: Sarilumab, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab, 200 or 400 mg subcutaneous injection
Trial: 36476193
Drug: Spirulina (SP)
DrugBank: Spirulina platensis (DB14744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (SP) 2 g per day for 5 weeks
Trial: 33904798
Drug: 1-day antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day antibiotics (ciprofloxacin)
Trial: 33904798
Drug: 3-day antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day antibiotics (ciprofloxacin)
Trial: 35340172
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody combined with total neoadjuvant chemoradiotherapy
Trial: 34511134
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg Q2W plus statin (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Trial: 34511134
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg Q2W plus statin
Trial: 34843806
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dexamethasone with 0.5% ropivacaine and 0.2% lignocaine
Trial: 35971069
Drug: Step function
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step function model fitted on data from all treatment arms
Trial: 36399083
Drug: Listening to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listening to self-selected music for 30 minutes daily for two weeks (Multi-Music Group - MG)
Trial: 36399083
Drug: Listening to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listening to lullabies for 30 minutes daily for two weeks (Lullaby Group - LG)
Trial: 36048417
Drug: Ad5‐nCoV (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5‐nCoV (5 × 10^10 viral particles/vial, 0.5 mL)
Trial: 33569869
Drug: Adventure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adventure therapy (AT)
Trial: 33569869
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (based on cognitive-behavioral therapy)
Trial: 35367469
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure at concentrations of 20, 50, and 150 μg/m3 for 4 hours
Trial: 35367469
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure at concentrations of 50 μg/m3 and above
Trial: 32372407
Drug: Post-foaming dental
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-foaming dental gel (Group 1: device-enhanced; Group 2: toothbrush)
Trial: 32372407
Drug: Post-foaming dental
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-foaming dental gel (Group 1: device-enhanced)
Trial: 32372407
Drug: Post-foaming dental
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-foaming dental gel (Group 2: toothbrush)
Trial: 32372407
Drug: Post-foaming dental
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-foaming dental gel (Group 1 and 2)
Trial: 34268908
Drug: Hydroxychloroquine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine with pantoprazole (40 mg once daily for 9 days)
Trial: 32460589
Drug: G. sylvestre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. sylvestre 300 mg b.i.d.
Trial: 35503591
Drug: 4 hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 hourly rotation of masks and prongs
Trial: 34853089
Drug: Ustekinumab (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (approximately 6 mg/kg single intravenous infusion, then subcutaneous injections of 90 mg every 8 weeks)
Trial: 32880201
Drug: Royal Jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Jelly (RJ) supplementation (3000 mg of fresh RJ equivalent)
Trial: 33906810
Drug: MR‐proADM guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR‐proADM guided arm (low MR‐proADM value ≤0.87 nmol/L)
Trial: 33906810
Drug: MR‐proADM guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR‐proADM guided arm (high MR‐proADM value >0.87 nmol/L)
Trial: 34416193
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine (two doses, 28 days apart)
Trial: 32969200
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (n=12) received mesalazine (60 mg kg−1 day−1) and oral probiotics (Lactobacillus casei Zhang, Lactobacillus plantarum P‐8, Bifidobacterium animalis subsp. lactis V9) twice daily for 12 weeks
Trial: 33296553
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound (LIPUS) administered twice weekly for 24 weeks
Trial: 35892316
Drug: Atrasentan (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan (dosage not specified)
Trial: 32466858
Drug: Senofilcon A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senofilcon A lenses with polyquaternium-based care solution (OPTI-FREE Replenish)
Trial: 35267097
Drug: 1.4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 ml 2% lidocaine + 0.4 ml (40 μg) dexmedetomidine (DEX)
Trial: 35267097
Drug: 1.4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 ml 2% plain lidocaine
Trial: 34429952
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of tranexamic acid (TXA) 500mg/5 mL, total 10 mL at the surgical site.
Trial: 33884617
Drug: Mentalisation-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalisation-based therapy (MBT)
Trial: 34710071
Drug: Pericoital tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pericoital tenofovir 1% gel
Trial: 34480579
Drug: Daridorexant 150
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant 150 mg
Trial: 34547081
Drug: Slower infusion
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slower infusion rate (333 mL/h)
Trial: 34547081
Drug: Control infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control infusion rate (999 mL/h)
Trial: 32715513
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) intervention, 8-week group-delivered
Trial: 34041527
Drug: Headgear activator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headgear activator treatment in mixed dentition (MD) starting at age 9
Trial: 34041527
Drug: Headgear activator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headgear activator treatment in late mixed dentition (LMD) starting at age 11
Trial: 32811168
Drug: XEN 63
RxNorm normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN 63 Gel Stent
Trial: 34419109
Drug: Simethicone solution
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone solution intake 31‐60 minutes before procedure (group 2)
Trial: 34419109
Drug: Simethicone solution
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone solution intake 20‐30 minutes before procedure (group 1)